Counteracting the Disease Continuum in Hormone-Sensitive Prostate Cancer – Tweetorial #4




Provided by Integrity Continuing Education, Inc.


Supported by independent educational grants from Astellas Pharma Global Development, Inc. and Pfizer Inc.


For decades, hormone-sensitive prostate cancer (HSPC) was largely ignored while clinicians waited for it to develop into castration-resistant metastatic disease (mCRPC). Until recently, there were no treatment options that showed significant survival benefit for HSPC and so progression to mCRPC was seen as almost inevitable; however, since 2015, effective treatment strategies have emerged as the new standard of care for HSPC. It is now thought that intervening earlier with these combinations—particularly with second-generation androgen receptor inhibitors—could reduce disease burden. This program will provide education on second-generation androgen receptor inhibitors in the treatment of prostate cancer.


Silke Gillessen Sommer, MD
Professor of Medicine
Medical & Scientific Director
Chief Physician
Oncology Institute of Southern Switzerland


Brian Rini, MD
Professor of Medicine
Chief of Clinical Trials
Vanderbilt Ingram Cancer Center
Nashville, Tennessee


Christopher Sweeney, MBBS
Professor of Medicine
Medical Oncology
Dana Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts


Release date: November 3, 2021
Expiration date: November 3, 2022
Estimated time to complete activity: 30 minutes



This educational activity has been designed to meet the needs of medical oncologists, urologists, primary care physicians, advanced practice providers, and other members of the multidisciplinary care team involved in the care and management of patients with prostate cancer.


Upon completion of this educational activity, participants should be able to:

  • Formulate a treatment strategy for earlier pharmacologic intervention in patients at risk for metastatic HSPC or who have undergone definitive therapy and experienced biochemical recurrence
  • Assess the evolving scientific evidence and best practice recommendations to guide management of patients in earlier stages of the prostate cancer disease continuum

There are no fees for participating and receiving CME credit for this activity. During the period of November 3, 2021 through November, 3, 2022 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.




Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this other activity for a maximum of 0.5 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Silke Gillessen Sommer, MD
Advisory Boards: AAA International SA, Astellas, Amgen, Bayer, Bristol-Myers Squibb, Janssen, Merck Sharp & Dohme, Orion Co., Pfizer, Roche, Telixpharma, Tolero Pharmaceuticals
Speakers’ Bureau: Janssen Cilag
Travel Support: ProteoMedix

Brian Rini, MD
Consulting Fees: Aravive, AVEO Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Pfizer
Contracted Research: AstraZeneca, Bristol-Myers Squibb, Exelixis, Merck, Pfizer

Christopher Sweeney, MBBS
Consulting Fees: Astellas, Bayer, Genentech Roche, Janssen, Lilly, Pfizer, Sanofi
Contracted Research: Astellas, Bayer, Dendreon, Janssen, Pfizer, Sanofi

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest